来源: Pharmaceutical Technology
Ascidian retains the freedom to pursue other neurological targets independently or with different collaborators. Credit: Komsan Loonprom / Shutterstock. 来源: Pharmaceutical Technology
The partnership will leverage Ascidian’s RNA exon editing platform to extend the therapeutic potential of the medicine beyond the capabilities of current gene editing technologies. Ascidian will grant Roche sole rights to utilise its RNA exon editing technology for undisclosed neurological targets. Ascidian will conduct discovery and some preclinical works together with Roche. Roche will assume responsibility for additional preclinical activities, alongside clinical development, production and commercialisation of the assets. See Also:FDA grants approval for Alexion’s NMOSD treatment 来源: Pharmaceutical Technology
来源: Pharmaceutical Technology
Ascidian is entitled to receive an upfront payment of $42m from Roche, and could receive up to $1.8bn in milestone payments on meeting research, clinical and commercial goals. Ascidian will earn royalty payments on global commercial product sales from Roche. Despite this exclusive arrangement for specific targets, Ascidian can pursue other neurological targets independently or with different collaborators. The platform developed by Ascidian is capable of editing RNA exons on a kilobase scale, enabling it to target large genes and those with a high degree of mutational variance. The technology preserves natural gene expression patterns and levels.
“The potential of treating disease by large-scale exon editing of RNA is vast. We look forward to working with the Roche team to develop first-in-class RNA exon editing medicines for multiple neurological diseases, with a mission and passion to relieve suffering and improve lives.” mRNA vaccine coverage on Pharmaceutical Technology (Or Clinical Trials Arena) is supported by Trilink. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepapermRNA capping: low cost, high reward
Are you aware of the latest mRNA capping techniques? The success of mRNA-based Covid vaccines has seen the technology boom in popularity – but capping is an essential part of the manufacturing process, and pharmaceutical firms face a range of choices on how to do it. This free whitepaper assesses differences in price, time, complexity and availability for the methods on offer – and provides essential insights on TriLink’s trailblazing CleanCap® approach. Fill in your details to find out more. Thank you.You will receive an email shortly. Please check your inbox to download the Whitepaper.
来源: Pharmaceutical Technology
By downloading this case study, you acknowledge that GlobalData may share your information with Trilink Thematic and that your personal data will be used as described in their Privacy Policy